Biotech entity
All 2 tracked stories fall under one category: clinical-trial. AbbVie is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The 22-day window averages about 0.6 stories each week. Source depth averages 2.5 original sources per story, versus 4.9 across the same-window beat baseline.
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: clinical-trial. AbbVie is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The 22-day window averages about 0.6 stories each week. Source depth averages 2.5 original sources per story, versus 4.9 across the same-window beat baseline. The 7 average consequence score is above the beat benchmark of 6.5 in the same window. We currently track 2 Biotech stories that mention Genmab, published between July 11, 2026 and August 1, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 130 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Genmab. Shared-story counts are live from our verified record — not editorial picks.
Clarification on US Primary Endpoint
Companies publicly disclosed the trial missed the US primary endpoint of overall survival.
EHA 2026 Presentation
Additional study results presented at the European Hematology Association Congress.
Topline Results Announced
Genmab and AbbVie released initial data from the Phase 3 EPCORE DLBCL-1 trial.
The Phase 3 EPCORE DLBCL-1 trial of epcoritamab failed its US overall survival endpoint, jeopardizing full approval and the drug's growing $300 million annual sales. This clarification deepens the competitive threat from other bispecifics with survival data.
Source: finanznachrichten.de · stockhouse.com
AbbVie and Genmab's bispecific antibody epcoritamab combined with lenalidomide delivered a hazard ratio of 0.40 in a pivotal DLBCL trial, setting the stage for regulatory filings and a potential second-line market expansion that could challenge CAR-T dominance and redefine the bispecific landscape.
Source: finanznachrichten.de · prnewswire.com
Genmab is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
